Novel systemic therapies for the treatment of psoriasis.

    Research output: Contribution to journalArticlepeer-review


    INTRODUCTION: The immunopathogenesis of psoriasis has led to the discovery and development of several promising treatment options for psoriasis, including those that target the IL-17 and IL-23 pathways as well as small molecules that act on intracellular signaling pathways including the Janus kinase inhibitor and phosphodiesterase-4 inhibitor. Studies have demonstrated efficacy although long-term risks are not fully known. This review looks at novel systemic therapies for psoriasis that have emerged recently. Areas covered: Systemic treatments for psoriasis that are in the late phase of development were reviewed, with the main focus on the efficacy and adverse effects of individual treatments. Expert opinion: The future of psoriasis treatment is likely to be based on clinical, genetic and immune biomarkers that will individualize treatment and may potentially optimize disease outcome.
    Original languageEnglish
    JournalExpert opinion on pharmacotherapy
    Publication statusPublished - 7 Nov 2015


    • IL-17
    • IL-23
    • JAK inhibitor
    • biologic
    • novel
    • phosphodiesterase-4 inhibitor
    • psoriasis
    • small molecules
    • systemic


    Dive into the research topics of 'Novel systemic therapies for the treatment of psoriasis.'. Together they form a unique fingerprint.

    Cite this